Skip to main content

Advertisement

SpringerLink
Log in

Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Nodal peripheral T-cell lymphomas (PTCLs) have particularly poor prognoses. Few data enabling establishment of an accepted standard treatment modality for PTCLs are available. We hypothesized that fludarabine-based regimens are tolerable and effective in treatment for nodal PTCLs. Therefore, this study was to analyze the toxicity of, response rate for, and outcome of treatment for nodal PTCLs with oral fludarabine, doxorubicin, and dexamethasone (FAD).

Methods

Patients with PTCLs received FAD every 28 days, consisting of oral fludarabine at 40 mg/m2 on days 1–3, doxorubicin at 50 mg/m2 on day 1, and oral dexamethasone at 20 mg/day on days 1–5. Patients who did not exhibit disease progression received at least four courses of treatment.

Results

Thirty-one of 35 patients with previously untreated nodal PTCLs enrolled in the study from 2007 to 2008 were evaluable. The incidence of grade 3–4 neutropenia was 55%. Nine patients had to have dose reductions of fludarabine and doxorubicin, none of whom had grade 3 or 4 toxic effects at the lower dose. Five of 31 patients had pneumonitis. No treatment-related mortality occurred. The response rate for the entire patient population was 71%, and the complete remission rate was 48%. The PFS and OS rates at 2 years were 54.2 and 77.1%, respectively. Four patients had died of cancer progression at the time of this analysis. The serum lactate dehydrogenase level had a significant effect on PFS and OS.

Conclusion

The FAD regimen had encouraging efficacy with an acceptable toxicity profile in patients with nodal PTCLs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Harris NL, Swerdlow S, Campo E, Jaffe ES, Stein H, Pileri S, Thiele J, Vardiman J (2008) The World Health Organization (WHO) classification of lymphoid neoplasms: what’s new? Ann Oncol 19:119

    Google Scholar 

  2. Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124–4130

    Article  PubMed  Google Scholar 

  3. Armitage JO, Vose JM, Weisenburger DD (2004) Towards understanding the peripheral T-cell lymphomas. Ann Oncol 15(10):1447–1449

    Article  PubMed  CAS  Google Scholar 

  4. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM (2004) Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15(10):1467–1475

    Article  PubMed  CAS  Google Scholar 

  5. Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, Bendandi M, Albo C, Caballero MD (2007) Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79(1):32–38

    Article  PubMed  Google Scholar 

  6. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20(9):1533–1538

    Article  PubMed  CAS  Google Scholar 

  7. Laport GG (2010) Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy. Curr Opin Oncol 22(5):409–413

    Article  PubMed  Google Scholar 

  8. Feyler S, Prince H, Pearce R (2007) The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study Bone Marrow Transplant 40:443–450

    CAS  Google Scholar 

  9. Corradini P, Dodero A, Zallio F (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22(11):2172–2176

    Article  PubMed  Google Scholar 

  10. Hast R, Jacobsson B, Petrescu A, Hjalmar V (1999) Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma 34(5–6):597–601

    PubMed  CAS  Google Scholar 

  11. Yamaguchi M, Kotani T, Nakamura Y, Ueda M (2006) Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. Int J Hematol 83(5):450–453

    Article  PubMed  Google Scholar 

  12. Rossi JF, van Hoof A, de Boeck K, Johnson SA, Bron D, Foussard C, Lister TA, Berthou C, Kramer MH, Littlewood TJ, Marcus RE, Deconinck E, Montillo M, Guibon O, Tollerfield SM (2004) Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 22(7):1260–1267

    Article  PubMed  CAS  Google Scholar 

  13. Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, Minami H, Utsunomiya A, Taniwaki M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Seriu T, Hotta T (2006) Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin’s lymphoma. J Clin Oncol 24(1):174–180

    Article  PubMed  CAS  Google Scholar 

  14. Damaraju D, Damaraju VL, Brun M, Mowles D, Kuzma M, Berendt RC, Sawyer MB, Cass CE (2008) Cytotoxic activities of nucleoside and nucleobase analog drugs in malignant mesothelioma: characterization of a novel nucleobase transport activity. Biochem Pharmacol 75(10):1901–1911

    Article  PubMed  CAS  Google Scholar 

  15. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1–10

    Article  PubMed  CAS  Google Scholar 

  16. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111(12):5496–5504

    Article  PubMed  CAS  Google Scholar 

  17. Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Agressives). Ann Oncol 1(1):45–50

    PubMed  CAS  Google Scholar 

  18. Herold M, Hieke K (2002) Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine. Eur J Health Econ 3(3):166–172

    Article  PubMed  CAS  Google Scholar 

  19. Disel U, Paydas S, Yavuz S, Karakoc E (2010) Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab. Chemotherapy 56(2):89–93

    Article  PubMed  CAS  Google Scholar 

  20. Helman DL Jr, Byrd JC, Ales NC, Shorr AF (2002) Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest 122(3):785–790

    Article  PubMed  Google Scholar 

  21. Vose JM (2008) Peripheral T-cell non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am 22(5):997–1005, x

    Google Scholar 

  22. Savage K, Ferreri AJ, Zinzani PL, Pileri SA (2010) Peripheral T-cell lymphoma—not otherwise specified. Crit Rev Oncol Hematol. doi:10.1016/j.critrevonc.2010.07.007

  23. Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, Dang NH (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103(10):2091–2098

    Article  PubMed  Google Scholar 

  24. Yung L, Cunningham D, Hancock B, Smith P, Maclennan K, Linch D, McMillan A (2004) Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI). Br J Cancer 91(4):695–698

    PubMed  CAS  Google Scholar 

  25. O’Connor OA (2010) Novel agents in development for peripheral T-cell lymphoma. Semin Hematol 47(Suppl 1):S11–S14

    Article  PubMed  Google Scholar 

  26. Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A, Matutes E (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92(2):271–272

    Article  PubMed  CAS  Google Scholar 

  27. de Totero D, Tazzari PL, Capaia M, Montera MP, Clavio M, Balleari E, Foa R, Gobbi M (2003) CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation. Haematologica 88(2):148–158

    PubMed  Google Scholar 

  28. Telek B, Rejto L, Kiss A, Batar P, Remenyi G, Rak K, Udvardy M (2002) Experience with fludarabine treatment and review of the literature. Orv Hetil 143(24):1459–1465

    PubMed  Google Scholar 

  29. Huang HQ, Peng YL, Lin XB, Sun XF, Lin TY, Xia ZJ, Li YH, Cai QQ, He YJ, Jiang WQ, Guan ZZ (2004) Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen. Ai Zheng 23(11 Suppl):1443–1447

    PubMed  Google Scholar 

  30. Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camos M, Colomo L, Espinosa I, Martinez S, Ribera JM, Martino R, Gutierrez-Garcia G, Montserrat E, Lopez-Guillermo A (2008) Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19(5):958–963

    Article  PubMed  CAS  Google Scholar 

  31. Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni F, Albertini P, Pileri SA, Tura S (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9(12):1351–1353

    Article  PubMed  CAS  Google Scholar 

  32. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110(7):2316–2323

    Article  PubMed  CAS  Google Scholar 

  33. Lawlor E, O’Briain DS, Finn T, Ward R, Rogers FM, O’Brien AA, Daly PA (1987) The simultaneous presentation of peripheral T-cell lymphoma and hairy cell leukemia. Cancer 60(7):1537–1544

    Article  PubMed  CAS  Google Scholar 

  34. Peng YL, Huang HQ, Lin XB, Xia ZJ, Li YH, Wang W, He YJ, Pan ZH, Jiang WQ, Guan ZZ (2004) Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen. Ai Zheng 23(8):943–946

    PubMed  Google Scholar 

  35. Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, Tsukada J, Shibata K, Tamura K (2010) THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study. Eur J Haematol 84(5):391–397

    Google Scholar 

Download references

Acknowledgments

We thank Bayer HealthCare for support free Fludarabine for enrolled patients. We thank Mr. Norwood Donald R, who is a scientific editor of department of scientific publications from MD Anderson cancer center of the USA, for her assistance in the language writing of this article.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Fudan University Shanghai Cancer center, 270 Dong-An Road, Shanghai, 200032, People’s Republic of China

    Xiao-Jian Liu, Ye Guo, Jun-Ning Cao, Xiang-Hua Wu, Jian Zhang & Xiao-Nan Hong

  2. Department of Pathology, Fudan University Shanghai Cancer center, 270 Dong-An Road, Shanghai, 200032, People’s Republic of China

    Xiao-Qiu Li & Chao-Fu Wang

  3. Department of Oncology, Shanghai Medical Collage, Fudan University, Shanghai, 200032, People’s Republic of China

    Xiao-Jian Liu, Ye Guo, Jun-Ning Cao, Xiang-Hua Wu, Jian Zhang, Xiao-Qiu Li, Chao-Fu Wang & Xiao-Nan Hong

  4. Department of Oncology, Zhejiang Provincial Cancer Hospital, 38 Guangji Road, Hangzhou, 310022, People’s Republic of China

    Yun Fan

  5. Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, 230022, People’s Republic of China

    Kang-Sheng Gu

Authors
  1. Xiao-Jian Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ye Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yun Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kang-Sheng Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun-Ning Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiang-Hua Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiao-Qiu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chao-Fu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiao-Nan Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao-Nan Hong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, XJ., Guo, Y., Fan, Y. et al. Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study. Cancer Chemother Pharmacol 69, 387–395 (2012). https://doi.org/10.1007/s00280-011-1711-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1711-z

Keywords

Search

Navigation